The scFv component, which targets the antigen, is introduced into CAR structures via lentivirus, with extensive scFv production achieved through “light chain shuffling.” Methods of affinity screening and efficacy assessment evaluate the affinity, proliferation, differentiation, and tumor-killing potential of CD38 CAR-T cells. Here, CD38 is linked to neoplasm.